Ionis director Joan Herman receives 5,220 shares

Ionis Pharmaceuticals director Joan E. Herman reported the vesting of 5,220 Restricted Stock Units on July 15, 2026, which were settled into 5,220 shares of common stock at $0.0000 per share.

Rhea-AI Filing Summary

Ionis Pharmaceuticals director Joan E. Herman reported the vesting of 5,220 Restricted Stock Units on July 15, 2026, which were settled into 5,220 shares of common stock at $0.0000 per share. Following this derivative exercise, she directly holds 51,306 common shares and 2,301 Restricted Stock Units.

Insider Trade Summary

5,220 shares exercised/converted

Exercise 2 txns

Insider HERMAN JOAN E

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F2, F3	5,220	$0.00	$0.00
Exercise	Common Stock F1	5,220	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 2,301 contracts (Direct); Common Stock — 51,306 shares (Direct)

Footnotes (3)

1. F1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
2. F2. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
3. F3. Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

Key Figures

Common shares acquired: 5220 shares Common shares held after transaction: 51306 shares Restricted Stock Units converted: 5220 Restricted Stock Units +2 more

5 metrics

Common shares acquired 5220 shares Shares of common stock received upon RSU vesting on 2026-07-15

Common shares held after transaction 51306 shares Direct Ionis common stock holdings after the July 15, 2026 transaction

Restricted Stock Units converted 5220 Restricted Stock Units RSUs exercised/converted into common stock on 2026-07-15

Restricted Stock Units remaining 2301 Restricted Stock Units RSU balance following the reported derivative exercise

Conversion price per share $0.0000 per share Exercise or conversion price for the Restricted Stock Units into common stock

Key Terms

Restricted Stock Unit, derivative security, contingent right

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction code description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

contingent right financial

"represents a contingent right to receive one share of Ionis common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity event did Ionis (IONS) director Joan E. Herman report?

Joan E. Herman reported the vesting of 5,220 Restricted Stock Units that were settled into 5,220 Ionis common shares. The transaction was recorded on July 15, 2026 as an exercise or conversion of a derivative security at $0.0000 per share.

How many Ionis (IONS) common shares does Joan E. Herman hold after this transaction?

After the reported vesting and share delivery, Joan E. Herman directly holds 51,306 shares of Ionis common stock. This total reflects her position immediately following the conversion of 5,220 Restricted Stock Units into an equal number of common shares.

How many Restricted Stock Units vested for Joan E. Herman at Ionis (IONS)?

A total of 5,220 Restricted Stock Units vested for Joan E. Herman. Each vested unit was settled into one share of Ionis common stock, or its equivalent cash value, as provided under the terms of the Restricted Stock Unit award.

How many Ionis (IONS) Restricted Stock Units remain outstanding for Joan E. Herman?

Following the conversion of 5,220 units, Joan E. Herman has 2,301 Restricted Stock Units remaining. These outstanding units continue to represent a contingent right to receive one share of Ionis common stock, or its equivalent cash value, per unit.

What key terms apply to the Ionis (IONS) Restricted Stock Units in this report?

Each Restricted Stock Unit represents a contingent right to receive one Ionis common share or its cash value. Units vest 100% on the first grant anniversary or next annual stockholder meeting, and are delivered on the July 15 following the vesting date in shares or cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERMAN JOAN E

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		M(1)		5,220(1)	A	$0.0	51,306	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.0(2)	07/15/2026		M			5,220	(3)	(3)	Common Stock	5,220	$0.0	2,301	D

Explanation of Responses:

1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

2. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

3. Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

	By: Patrick R. O'Neil, attorney-in-fact For: Joan E. Herman	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)